Tracer library / [111In]BQ7859

[111In]BQ7859

Also written as [In-111]In-BQ7859

Radionuclide: In-111 t½ 4031.6 min
Modality: Therapy
Production route: —
Stage: Reported once
Syntheses indexed: 1

Prostate cancer Preclinical only, no clinical indication yet

What it is

Compound class: Glu-urea-Lys PSMA-targeting urea-based radioligand with NOTA chelator
Target / mechanism: Prostate-specific membrane antigen (PSMA) PMID 35631684
Clinical application: Prostate cancer PMID 35631684
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	—	98.9 ± 0.6%	—	BQ7859…BQ7859 (Glu-urea-Lys-2-naphthyl-L-alanine-L-Tyr-8Aoc-Lys(NOTA)-acetamide)	35631684 2022 Pharmaceutics The reaction mixture was left for 30 min at 85 °C. - radiolabelled with indium-111, with an average yield of 98.9 ± 0.6% (Table 2)

Need this precursor?We can point you to suppliers for [111In]BQ7859, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 35631684. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 35631684: 'BQ7859 (Glu-urea-Lys-2-naphthyl-L-alanine-L-Tyr-8Aoc-Lys(NOTA)-acetamide)'.